piracetam has been researched along with Delayed Effects, Prenatal Exposure in 15 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 7.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 5.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| " Children exposed to monotherapy levetiracetam (n = 42), topiramate (n = 27), or valproate (n = 47) and a group of children born to women who had untreated epilepsy (n = 55) were enrolled retrospectively from the UK Epilepsy and Pregnancy Register." | 3.83 | Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. ( Baker, GA; Bromley, RL; Calderbank, R; Cheyne, CP; Clayton-Smith, J; García-Fiñana, M; Irwin, B; Morrow, JI; Rooney, C; Shallcross, R; Trayner, P, 2016) |
| "To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy." | 3.80 | In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. ( Baker, GA; Bromley, RL; Cheyne, CP; García-Fiñana, M; Irwin, B; Morrow, J; Shallcross, R, 2014) |
| "Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97)." | 3.77 | Child development following in utero exposure: levetiracetam vs sodium valproate. ( Baker, GA; Bonnett, LJ; Bromley, RL; Irwin, B; Morrow, J; Shallcross, R, 2011) |
| "We aimed to establish the physical, motor, and cognitive teratogenic effect of levetiracetam exposure throughout pregnancy in rats." | 3.76 | Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring. ( Bas, DB; Bilge, S; Bozkurt, A; Ciftcioglu, E; Ilkaya, F; Ozyurek, H, 2010) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 3.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "The current evidence suggests that the overall risk of major malformation after first trimester exposure to Levetiracetam is within the population baseline risk of 1-3%, with no apparent adverse effects on long term child development." | 2.50 | The fetal safety of Levetiracetam: a systematic review. ( Chaudhry, SA; Jong, G; Koren, G, 2014) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 1.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| "Aniracetam was administered to 1-month-old rats, demonstrating a prolonged (2 months) therapeutic effect, observed in rats aged 3 months." | 1.31 | Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? ( Vaglenova, J; Vesselinov Petkov, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nemes, AD | 1 |
| O'Dwyer, R | 1 |
| Najm, IM | 1 |
| Ying, Z | 1 |
| Gonzalez-Martinez, J | 1 |
| Alexopoulos, AV | 1 |
| Klein, P | 1 |
| Mathews, GC | 1 |
| Shallcross, R | 3 |
| Bromley, RL | 3 |
| Cheyne, CP | 2 |
| García-Fiñana, M | 2 |
| Irwin, B | 4 |
| Morrow, J | 3 |
| Baker, GA | 3 |
| Chaudhry, SA | 1 |
| Jong, G | 1 |
| Koren, G | 1 |
| Janszky, J | 1 |
| Calderbank, R | 1 |
| Rooney, C | 1 |
| Trayner, P | 1 |
| Clayton-Smith, J | 1 |
| Morrow, JI | 1 |
| Ozyurek, H | 1 |
| Bozkurt, A | 1 |
| Bilge, S | 1 |
| Ciftcioglu, E | 1 |
| Ilkaya, F | 1 |
| Bas, DB | 1 |
| Bonnett, LJ | 1 |
| Long, L | 1 |
| Isoherranen, N | 1 |
| Spiegelstein, O | 1 |
| Bialer, M | 1 |
| Zhang, J | 1 |
| Merriweather, M | 1 |
| Yagen, B | 1 |
| Roeder, M | 1 |
| Triplett, AA | 1 |
| Schurig, V | 1 |
| Finnell, RH | 1 |
| Hunt, S | 1 |
| Craig, J | 1 |
| Russell, A | 1 |
| Guthrie, E | 1 |
| Parsons, L | 1 |
| Robertson, I | 1 |
| Waddell, R | 1 |
| Morrison, PJ | 1 |
| Trofimov, SS | 3 |
| Ostrovskaia, RU | 3 |
| Kravchenko, EV | 2 |
| Smol'nikova, NM | 2 |
| Bondarenko, NA | 1 |
| Kutepova, OA | 1 |
| Nemova, EP | 2 |
| Voronina, TA | 2 |
| Chepkova, AN | 1 |
| Smoĺnikova, NI | 1 |
| Gudasheva, TA | 1 |
| Vaglenova, J | 1 |
| Vesselinov Petkov, V | 1 |
1 review available for piracetam and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
The fetal safety of Levetiracetam: a systematic review.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Fetal Diseases; Fetus; Humans; Leveti | 2014 |
14 other studies available for piracetam and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia.
Topics: Acetamides; Animals; Anticonvulsants; Electroencephalography; Female; GABA Antagonists; Lacosamide; | 2017 |
Antiepileptic drugs and neurocognitive development.
Topics: Anticonvulsants; Child Development; Female; Humans; Language Development; Levetiracetam; Male; Pirac | 2014 |
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Topics: Adult; Anticonvulsants; Child Development; Child, Preschool; Epilepsy; Female; Humans; Language Deve | 2014 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Cross-Sectional Studies; Epilepsy; Female; Follo | 2016 |
Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring.
Topics: Animals; Anticonvulsants; Avoidance Learning; Cognition; Exploratory Behavior; Female; Learning; Lev | 2010 |
Child development following in utero exposure: levetiracetam vs sodium valproate.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Humans; Infant; L | 2011 |
Levetiracetam monotherapy during pregnancy: a case series.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Levetiracet | 2003 |
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Topics: Animals; Butyrates; Disease Models, Animal; Female; Fetus; Levetiracetam; Mice; Piracetam; Pregnancy | 2003 |
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Infant, | 2006 |
[Behavior disorders in rats exposed to intrauterine hypoxia, and their correction by postnatal treatment with piracetam].
Topics: Animals; Behavior, Animal; Female; Fetal Hypoxia; Learning Disabilities; Memory Disorders; Piracetam | 1993 |
[Piracetam as a corrector of long-term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy].
Topics: Animals; Avoidance Learning; Ethanol; Female; Learning Disabilities; Male; Nootropic Agents; Piracet | 1996 |
[Damage to plastic properties of synaptic transmission in the rat hippocampus resulting from prenatal hypoxia, and their normalization by treatment with nootropic dipeptides].
Topics: Animals; Dipeptides; Female; Hippocampus; Hypoxia; Male; Neuronal Plasticity; Nootropic Agents; Pira | 1995 |
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Disease Models, Animal; Female; Learning Disabil | 2001 |